RSV Vaccine Eligibility Expands - Scorecard - MDSpire

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 3 min

Share

Clinical Scorecard: RSV Vaccine Eligibility Expands

At a Glance

CategoryDetail
ConditionRespiratory Syncytial Virus (RSV) Infection
Key MechanismsVaccine contains recombinant RSV glycoprotein F stabilized in the prefusion conformation with AS01E adjuvant system.
Target PopulationAdults aged 18 to 49 years at increased risk for RSV-related lower respiratory tract disease.
Care SettingOutpatient and emergency department settings.

Key Highlights

  • FDA expanded Arexvy vaccine indication to adults aged 18-49 at increased risk.
  • Approximately 21 million adults under 50 have risk factors for severe RSV.
  • RSV causes an estimated 17,000 hospitalizations annually in adults aged 18-49.

Guideline-Based Recommendations

Diagnosis

  • Assess risk factors for severe RSV infection in adults.

Management

  • Administer Arexvy vaccine to eligible adults aged 18-49 at increased risk.

Monitoring & Follow-up

  • Monitor for adverse events post-vaccination, particularly within 4 days.

Risks

  • Adverse events may include injection site pain, fatigue, myalgia, headache, and arthralgia.

Patient & Prescribing Data

Adults aged 18 to 49 years with chronic medical conditions.

Vaccine efficacy demonstrated in phase 3 trials; safety profile consistent with earlier studies.

Clinical Best Practices

  • Evaluate patients for chronic conditions that increase RSV risk.
  • Educate patients on the importance of vaccination against RSV.

Related Resources & Content

Original Source(s)

RSV Vaccine Eligibility Expands

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis

Amoxicillin-clavulanate was not linked to lower treatment failure but was associated with a slightly higher risk of secondary infections compared with amoxicillin in adults with uncomplicated acute sinusitis.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.